COMUNICADO: Janssen solicita la aprobación de anti-Interleuquina-23 para el tratamiento de la psoriasis (y 2)

1. Sofen H, et al. Guselkumab (an IL-23-specific mAb) demonstrates clinical
and molecular response in patients with moderate-to-severe psoriasis. J
Allergy Clin Immunol 2014;133:1032-40.
2. National Psoriasis Foundation. Psoriasis Fact Sheet.
https://www.psoriasis.org/sites/default/files/psoriasis_fact_sheet.pdf
[https://www.psoriasis.org/sites/default/files/psoriasis_fact_sheet.pdf].
Consultado en noviembre de 2016
3. Ortonne J, et al. Alefacept: a novel and selective biologic agent for the
treatment of chronic plaque psoriasis. Eur J Dermatol 2004;14:41-45.
4. World Health Organization, Global Report on Psoriasis.
http://apps.who.int/iris/bitstream/10665/204417/1/9789241565189_eng.pdf?u
a=1
[http://apps.who.int/iris/bitstream/10665/204417/1/9789241565189_eng.pdf?
ua=1]. Consultado en noviembre de 2016
5. A Study of Guselkumab in the Treatment of Participants With Moderate to
Severe Plaque-Type Psoriasis (VOYAGE 1).
https://clinicaltrials.gov/ct2/show/NCT02207231
[https://clinicaltrials.gov/ct2/show/NCT02207231]. Consultado en
noviembre de 2016
6. A Study of Guselkumab in the Treatment of Participants With Moderate to
Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment
(VOYAGE 2). https://clinicaltrials.gov/ct2/show/NCT02207244
[https://clinicaltrials.gov/ct2/show/NCT02207244]. Consultado en
noviembre de 2016
7. A Study of Guselkumab in Participants With Moderate to Severe Plaque-type
Psoriasis and an Inadequate Response to Ustekinumab (NAVIGATE).
https://clinicaltrials.gov/ct2/show/NCT02203032
[https://clinicaltrials.gov/ct2/show/NCT02203032]. Consultado en
noviembre de 2016
8. A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate
to Severe Plaque-type Psoriasis (X-PLORE).
https://clinicaltrials.gov/ct2/show/NCT01483599
[https://clinicaltrials.gov/ct2/show/NCT01483599]. Consultado en
noviembre de 2016
9. National Psoriasis Foundation. People of All Races Overcome Psoriatic
Disease.
https://www.psoriasis.org/advance/features/people-of-all-races-overcome-t
he-challenge-of-psoriatic-diseases
[https://www.psoriasis.org/advance/features/people-of-all-races-overcome-
the-challenge-of-psoriatic-diseases]. Consultado en noviembre de 2016
10. The Psoriasis and Psoriatic Arthritis Alliance (PAPAA). About Psoriasis.
http://www.papaa.org/resources/about-psoriasis
[http://www.papaa.org/resources/about-psoriasis]. Consultado en
noviembre de 2016.

Contacto de Medios: Contactos de Inversión:
------------------- -----------------------

Brian Kenney Joseph J. Wolk

Oficina: 215-628-7010 Johnson & Johnson

Móvil: 215-620-0111 Oficina: 732-524-1142

Emily Bone Lesley Fishman

Móvil: +44 7876 394360 Johnson & Johnson

ebone1@its.jnj.com Oficina: 732-524-3922

Sitio Web: http://www.janssen.com/